Search IconSearch

Tag: anti-VEGF

Closeup of an eye looking at a needle preparing to inject medication into the eyeball

Measuring the Impact of Ongoing Aflibercept Treatment in Diabetic Retinopathy

Study highlights the value of quantitative ultra-widefield angiography

22-EYE-3438365 CQD-Fluid volatility in nAMD-Ehlers

Exudative Stability Key to Anti-VEGF Outcome in nAMD

Advanced OCT features may help individualize treatment intervals

22-EYE-3438364 CQD _ OCT-based imaging biomarkers650x450

Unlocking Precision Medicine in RVO: When Anti-VEGF Therapy Isn’t Effective

Intraretinal fluid volumes and other features detectable with OCT may help predict treatment response


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-EYE-3141638 CQD-EYP-1901 with vorolanib for maintenance of nAMD

DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD

53% of participants didn’t need anti-VEGF for six months or longer

21-EYE- 2468445- CQD – Faricimab in Neovascular

Effect of New Therapy Lasts Longer for Patients with Neovascular Age-Related Macular Degeneration

Faricimab every 16 weeks offers similar benefits as aflibercept every eight weeks


Even Brief Delays in Intravitreal Injection Can Cause Vision Loss

Patients with diabetic eye disease are most affected


Retinal Leakage Pattern and Vascular Tortuosity May Predict Durability of Anti-VEGF Therapy

Radiomics analysis suggests underlying subvisual features may encode information related to tolerance of interval extension in retinal vascular disease


Consequences of Lapse in Anti-VEGF Therapy During the COVID-19 Pandemic

Studies evaluate patients who missed treatments for diabetic macular edema and neovascular age-related macular degeneration

BackPage 1 of 2Next